The initiation of a merger inquiry by the CMA into Viatris's merger with Theramex suggests a significant focus on competition concerns within the UK market. While the outcome is uncertain, this regulatory scrutiny could lead to delays or modifications in the merger process, affecting Viatris's strategic plans and potentially its stock price. However, without specific findings or actions from the CMA, the immediate impact on Viatris's stock is likely neutral, pending further developments.